Kaouthar Lbiati, MD

Vice President, Corporate & Product Strategy

Dr. Lbiati is a multi-functional executive with a unique combination of scientific, business, policy & health economics skills. Over the last decade, she has been focused on the areas of oncology, immuno-oncology, malignant hematology-oncology products and health economics research. Her unique educational background and experience provides her with a broad perspective on science, medicine, business and health economics that has allowed her to develop insights and strategies that are broader and more substantive than most professionals in her field, and as such, she served in leadership roles at 3 of the world's leading pharmaceutical and biotechnology organizations in oncology: Amgen, Glaxo Smith Kline (GSK), Sanofi. Her roles revolved around Global Medical Affairs, Strategic planning, Health Economics and Outcomes Research (HEOR)/Market access and spanned different countries (United States, France, Dubai, and the United Kingdom). Since August 2020, she is Vice President Corporate Strategy & development at Cytovia Therapeutics with a focus on creating innovative portfolio development, partnerships and funding strategies with in mind to enable access globally of a large number of patients with cancer to highly innovative and curative cell therapies.

Dr Lbiati supported the registration and launch in the US, EU and MENA respectively of the following innovative cancer drugs: Blincyto®, Jevtana®, Votrient®. In 2016, as a member of the Global HEOR and Market Access Gene Therapy Team, she evaluated the clinical effectiveness and value of GSK’s gene therapy treatments for both ADA-SCID & beta-thalassemia, to guide decision making on divestment and empower key decision makers in their quest for effective drug treatments at lower costs, in a context of value-based evaluations and healthcare system. Strimvelis® was approved by EMA in the treatment of ADA-SCID (an orphan disease).

Dr. Lbiati has served as Strategic Advisor to biotech companies and venture capital firms. On September 21st, 2012 Dr. Lbiati was invited by the award-wining Renaloo working group to join the roundtable panel where she shared insights on how to integrate successfully the voice of the patient into research and drug development and to effectively consolidate partnerships between academia, patients’ advocacy groups, regulators and the pharma industry. In 2017, she held the role of Director Strategic Market Access at Amaris, a global consulting company providing solutions for world’s leading pharmaceutical organizations. In 2018, Dr Lbiati also served as a consultant to investment firms, such as Forepont Capital Partners, being brought in specifically to assess and evaluate new medical technologies under consideration for investment. From August 2019 to March 2020, she served as a Strategic Advisor, Consultant for Steba biotech. In this capacity she designed TOOKAD® integrated clinical development plan beyond Phase 1 in five indications for solid tumors ($75m investments over 6 years) and collaborated successfully with prominent international experts from MSKCC (USA) & the Weizmann Institute (Israel).

Dr. Lbiati earned a Doctorate of Medicine (MD) from Mohammed V University in Rabat/Morocco in 2006 followed by a fellowship in oncology at the Gustave Roussy Institute (IGR) in Paris. In 2009, she obtained a Specialized Executive Master’s degree in Strategy & Management from ESSEC Business School in Paris followed by a Masters of Science in International Policy and Health Economics from the London School of Economics (LSE) in 2017. She is currently pursuing the “Leading with Finance” program at Harvard Business School.